

Amendments to the Claims:

1. (currently amended) An isolated and purified-poly(ADP-ribose) polymerase (PARP) homolog comprising human PARP2 (SEQ ID NO: 2) or a functional equivalent thereof which is at least 85% homologous thereto, exhibits poly(ADP-ribose)-synthesizing activity, and has an amino acid sequence which
 - a) has a functional NAD⁺ binding domain comprising the sequence motif
PX_n(S/T)GX₃GKGIYFA (SEQ ID NO:11)
in which n is an integral value from 1 to 5, and the X radicals are, independently of one another, any amino acid;and
 - b) lacks a zinc finger sequence motif of the ~~general~~ formula
CX₂CX_mHX₂C (SEQ ID NO:30)
in which m is an integral value of 28 or 30, and the X radicals are, independently of one another, any amino acid.
2. (currently amended) The PARP homolog as claimed in claim 1, wherein the functional NAD⁺ binding domain comprises ~~one of the following general~~ sequence motifs:
(S/T)XGLR(I/V)XPX_n(S/T)GX₃GKGIYFA (SEQ ID NO:12) ~~or~~
~~LLWHG(S/T)X₂IL(S/T)XGLR(I/V)XPX_n(S/T)GX₃GKGIYFA₂SKSAXY (SEQ ID NO:13)~~
in which n is an integral value from 1 to 5, and the X radicals are, independently of one another, any amino acid.
3. (currently amended) The PARP homolog as claimed in claim 1, further comprising ~~at least another one of the following~~ part-sequence motifs:
LX₉NX₂YX₂QLLX(D/E)X_{10/11}WGRVG (SEQ ID NO: 15);
~~AX₃FXX₄KTXNXWX₃FX₃PXK (SEQ ID NO:16);~~

$QXL(I/L)X_2IX_9MX_{10}PLGKLX_3QIX_6L$ (SEQ ID NO:17);

$FYTXIPHXFGX_3PP$ (SEQ ID NO:18); and

$KX_3LX_2LXDIEXAX_2L$ (SEQ ID NO:19);

in which the X radicals are, independently of one another, any amino acid.

4-32. (canceled)

33. (new) The PARP homolog as claimed in claim I, wherein the functional NAD^+ binding domain comprises the following sequence motif:

$LLWHG(S/T)X_7IL(S/T)XGLR(I/V)XPX_n(S/T)GX_3GKGIYFAX_3SKSAXY$ (SEQ ID NO:13)

in which n is an integral value from 1 to 5, and

the X radicals are, independently of one another, any amino acid.

34. (new) The PARP homolog as claimed in claim I further comprising part-sequence motif

$AX_3FXKX_4KTXNXWX_5FX_3P XK$ (SEQ ID NO:16)

in which the X radicals are, independently of one another, any amino acid.

35. (new) The PARP homolog as claimed in claim I further comprising part-sequence motif

$XL(I/L)X_2IX_9MX_{10}PLGKLX_3QIX_6L$ (SEQ ID NO:17)

in which the X radicals are, independently of one another, any amino acid.

-
36. (new) The PARP homolog as claimed in claim I further comprising part-sequence motif

$FYTXIPHXFGX_3PP$ (SEQ ID NO:18)

in which the X radicals are, independently of one another, any amino acid.

37. (new) The PARP homolog as claimed in claim I further comprising part-sequence motif

$KX_3LX_2LXDIEXAX_2L$ (SEQ ID NO:19)

in which the X radicals are, independently of one another, any amino acid.


38. (new) An isolated poly(ADP-ribose) polymerase (PARP) homolog comprising human PARP2 (SEQ ID NO: 2) or a functional equivalent thereof which is at least 85% homologous thereto, exhibits poly(ADP-ribose)-synthesizing activity, and has an amino acid sequence which

- a) has a functional NAD^+ binding domain comprising the sequence motif $\text{PX}_n(\text{S/T})\text{GX}_3\text{GKGIYFA}$ (SEQ ID NO:11) in which n is an integral value from 1 to 5, and the X radicals are, independently of one another, any amino acid;

and

- b) lacks a zinc finger sequence motif of the formula $\text{CX}_2\text{CX}_m\text{HX}_2\text{C}$ (SEQ ID NO:30) in which m is an integral value of 28 or 30, and the X radicals are, independently of one another, any amino acid

further comprising a leucine zipper-like sequence motif:



wherein X radicals are, independently of one another, any amino acid.

39. (new) The PARP homolog as claimed in claim 38 further comprising at least one of the following part-sequence motifs:

$\text{LX}_9\text{NX}_2\text{YX}_2\text{QLLX}(\text{D/E})\text{X}_{10-11}\text{WGRVG}$ (SEQ ID NO: 15),

$\text{AX}_3\text{FXKX}_4\text{KTXNXWX}_3\text{FX}_3\text{PXX}$ (SEQ ID NO:16),

$\text{QXL}(\text{I/L})\text{X}_2\text{IX}_9\text{MX}_{10}\text{PLGKLX}_3\text{QIX}_6\text{L}$ (SEQ ID NO:17),

$\text{FYTIXIPHXFGX}_3\text{PP}$ (SEQ ID NO:18), and

$\text{KX}_3\text{LX}_2\text{LXDIEAX}_2\text{L}$ (SEQ ID NO:19)

in which the X radicals are, independently of one another, any amino acid.

40. (new) The PARP homolog as claimed in claim 38 further comprising part-sequence motifs:

LX₉NX₂YX₂QLLX(D/E)X_{10/11}WGRVG (SEQ ID NO: 15)
AX₃FXXKX₄KTXNXWX₃FX₃PXK (SEQ ID NO:16),
QXL(I/L)X₂IX₉MX₁₀PLGKLX₃QIX₆L (SEQ ID NO:17),
FYTXIPHXFGX₃PP (SEQ ID NO:18), and
KX₃LX₂LXDIEXAX₂L (SEQ ID NO:19)

in which the X radicals are, independently of one another, any amino acid.

41. (new) The PARP homolog as claimed in claim 38 further comprising part-sequence motifs:

LX₉NX₂YX₂QLLX(D/E)X_{10/11}WGRVG (SEQ ID NO: 15)
AX₃FXXKX₄KTXNXWX₃FX₃PXK (SEQ ID NO:16),
QXL(I/L)X₂IX₉MX₁₀PLGKLX₃QIX₆L (SEQ ID NO:17),
FYTXIPHXFGX₃PP (SEQ ID NO:18), and
KX₃LX₂LXDIEXAX₂L (SEQ ID NO:19)

in which the X radicals are, independently of one another, any amino acid, wherein

LX₉NX₂YX₂QLLX(D/E)X_{10/11}WGRVG

is closest to the N terminus.

42. (new) The PARP homolog as claimed in claim 1 further comprising part-sequence motifs:

LX₉NX₂YX₂QLLX(D/E)X_{10/11}WGRVG (SEQ ID NO: 15)
AX₃FXXKX₄KTXNXWX₃FX₃PXK (SEQ ID NO:16),
QXL(I/L)X₂IX₉MX₁₀PLGKLX₃QIX₆L (SEQ ID NO:17),
FYTXIPHXFGX₃PP (SEQ ID NO:18), and
KX₃LX₂LXDIEXAX₂L (SEQ ID NO:19)

in which the X radicals are, independently of one another, any amino acid.

43. (new) The PARP homolog as claimed in claim 1 further comprising part-sequence motifs:

LX₉NX₂YX₂QLLX(D/E)X_{10/11}WGRVG (SEQ ID NO: 15)

AX₃FXKX₄KTXNXWX₅FX₃PXK (SEQ ID NO:16),

QXL(I/L)X₂LX₉MX₁₀PLGK LX₃QIX₆L (SEQ ID NO:17),

FYTXIPHXFGX₃PP (SEQ ID NO:18), and

KX₃LX₂LXDIEXAX₂L (SEQ ID NO:19)

in which the X radicals are, independently of one another, any amino acid, wherein

LX₉NX₂YX₂QLLX(D/E)X_{10/11}WGRVG

is closest to the N terminus.

44. (new) The PARP homolog as claimed in claim 1 further comprising at least one of the following:

GX₃LXVALG,

GX₂SX₄GX₃PX_aLXGX₂V, and

E(Y/F)X₂YXYX₃QXYLL

in which a is 7 to 9 and

X is any amino acid.

45. (new) The PARP homolog as claimed in claim 1 further comprising

GX₃LXEVALG,

GX₂SX₄GX₃PX_aLXGX₂V, and

E(Y/F)X₂YX₃QX₄YLL

in which a is 7 to 9 and

X is any amino acid.

46. (new) The PARP homolog as claimed in claim 1 further comprising

GX₃LXEVALG,
GX₂SX₄GX₃PX_aLXGX₂V, and
E(Y/F)X₂YX₃QX₄YLL

in which a is 7 to 9 and

X is any amino acid, wherein

E(Y/F)X₂YX₃QX₄YLL

is closest to the C terminus.

47. (new) An isolated poly(ADP-ribose) polymerase (PARP) homolog comprising human PARP2 (SEQ ID NO: 2) or a functional equivalent thereof which is at least 85% homologous thereto, exhibits poly(ADP-ribose)-synthesizing activity, and has an amino acid sequence which
- a) has a functional NAD⁺ binding domain comprising the sequence motif
PX_n(S/T)GX₃GKGIYFA (SEQ ID NO:11)
in which n is an integral value from 1 to 5, and the X radicals are, independently of one another, any amino acid;
 - and
 - b) lacks a zinc finger sequence.
48. (new) The PARP homolog as claimed in claim 47 wherein said PARP lacks a zinc finger sequence motif of the formula
-
- CX₂CX_mHX₂C (SEQ ID NO:30)
- in which m is an integral value of 28 or 30, and
the X radicals are, independently of one another, any amino acid.
49. (new) The PARP homolog as claimed in claim 47 wherein the functional NAD⁺ binding domain comprises the following sequence motif:
- (S/T)XGLR(I/V)XPX_n(S/T)GX₃GKGIYFA (SEQ ID NO:12)

in which n is an integral value from 1 to 5, and
the X radicals are, independently of one another, any amino acid.

50. (new) The PARP homolog as claimed in claim 47 wherein the functional NAD⁺ binding domain comprises the following sequence motif:

LLWHG(S/T)X₇IL(S/T)XGLR(I/V)XPX_n(S/T)GX₃GKGIYFAX₃SKSAXY (SEQ ID NO:13)

in which n is an integral value from 1 to 5, and
the X radicals are, independently of one another, any amino acid.

51. (new) The PARP homolog as claimed in claim 47 further comprising a leucine zipper-like sequence:

(L/V)X₆LX₆LX₆L

wherein X radicals are, independently of one another, any amino acid.

52. (new) The PARP homolog as claimed in claim 51 further comprising at least one of the following part-sequence motifs:

LX₉NX₂YX₂QLLX(D/E)X_{10/11}WGRVG (SEQ ID NO: 15),

AX₃FXXKX₄KTXNXWX₃FX₃PXK (SEQ ID NO:16),

QXL(I/L)X₂IX₉MX₁₀PLGK LX₃QIX₆L (SEQ ID NO:17),

FYTXIPHXFGX₃PP (SEQ ID NO:18), and

KX₃LX₂LXDIEXAX₂L (SEQ ID NO:19)

in which the X radicals are, independently of one another, any amino acid.

53. (new) The PARP homolog as claimed in claim 51 further comprising:

LX₉NX₂YX₂QLLX(D/E)X_{10/11}WGRVG (SEQ ID NO: 15),

AX₃FXXKX₄KTXNXWX₃FX₃PXK (SEQ ID NO:16),

QXL(I/L)X₂IX₉MX₁₀PLGK LX₃QIX₆L (SEQ ID NO:17),

FYTXIPHXFGX₃PP (SEQ ID NO:18), and

KX₃LX₂LXDIEAX₂L (SEQ ID NO:19)

in which the X radicals are, independently of one another, any amino acid.

54. (new) The PARP homolog as claimed in claim 51 further comprising:

LX₉NX₂YX₂QLLX(D/E)X_{10/11}WGRVG (SEQ ID NO: 15),

AX₃FXKX₄KTXNXWX₅FX₃PXK (SEQ ID NO:16),

QXL(I/L)X₂IX₉MX₁₀PLGKLX₃QIX₆L (SEQ ID NO:17),

FYTXIPHXFGX₃PP (SEQ ID NO:18), and

KX₃LX₂LXDIEAX₂L (SEQ ID NO:19)

in which the X radicals are, independently of one another, any amino acid, wherein

LX₉NX₂YX₂QLLX(D/E)X_{10/11}WGRVG

is closest to the N terminus.

55. (new) The PARP homolog as claimed in claim 47 further comprising at least one of the following:

GX₃LXVALG,

GX₂SX₄GX₃PX₉LXGX₂V, and

E(Y/F)X₂YX₃QX₄YLL

in which a is 7 to 9 and

X is any amino acid.

56. (new) The PARP homolog as claimed in claim 47 further comprising

GX₃LXEVALG,

GX₂SX₄GX₃PX₉LXGX₂V, and

E(Y/F)X₂YX₃QX₄YLL

in which a is 7 to 9 and

X is any amino acid.

57. (new) The PARP homolog as claimed in claim 47 further comprising

GX₃LXEVALG,
GX₂SX₄GX₃PX_aLXGX₂V, and
E(Y/F)X₂YX₃QX₄YLL

in which a is 7 to 9 and

X is any amino acid, wherein

E(Y/F)X₂YX₃QX₄YLL

is closest to the C terminus.

58. (new) The PARP homolog as claimed in claim 51 further comprising at least one of the following:

GX₃LXVALG,
GX₂SX₄GX₃PX_aLXGX₂V, and
E(Y/F)X₂YX₃QX₄YLL

in which a is 7 to 9 and

X is any amino acid.

59. (new) The PARP homolog as claimed in claim 51 further comprising

GX₃LXEVALG,
GX₂SX₄GX₃PX_aLXGX₂V, and
E(Y/F)X₂YX₃QX₄YLL

in which a is 7 to 9 and

X is any amino acid.

60. (new) The PARP homolog as claimed in claim 51 further comprising

GX₃LXEVALG,
GX₂SX₄GX₃PX_aLXGX₂V, and

Application No.: 09/701,586

Inventor: Kock et al.

Reply to Office Action of 11 January 2006

Docket No.: 49100

E(Y/F)X₂YX₃QX₄YLL

in which a is 7 to 9 and

X is any amino acid, wherein

E(Y/F)X₂YX₃QX₄YLL

is closest to the C terminus.